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This article is the second in a series of two publications relating to the European 
Crohn’s and Colitis Organisation [ECCO] evidence-based consensus on the 
management of Crohn’s disease. The first article covers medical management; the 
present article addresses surgical management, including preoperative aspects and 
drug management before surgery. It also provides technical advice for a variety of 
common clinical situations. Both articles together represent the evidence-based 
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Introduction 
The incidence and prevalence of Crohn’s disease [CD] is rising globally, with yearly 
increases in incidence ranging from 4–15% over the last three decades1. A cure 
remains elusive and efficient management of CD is essentially multidisciplinary and 
interprofessional. At least half of patients with CD undergo one or more surgical 
procedures during their lifetime. CD patients frequently suffer from malnutrition, 
psychological comorbidities, and may have to live with a stoma2-5. Care for CD has 
become more complex for both medical and surgical disciplines. Several new drugs 
have entered the market and surgical subspecialization for inflammatory bowel disease 
has evolved. The best possible outcomes are currently achieved within dedicated expert 
centres providing personalized medicine6-10. Care for CD is exemplary in an interrelated 
clinical world where the actions of individual health care providers need coordination, 
common knowledge, and shared expectations to optimize clinical management and 
research in terms of diagnosis, treatment, and side-effects. The European Crohn’s and 
Colitis Organisation [ECCO] provides an interdisciplinary framework with the present 
evidence-based consensus guidelines to inform and guide clinicians and allied health 
care providers caring for patients with CD. The present guidelines focus on surgery for 
CD, including preoperative aspects and drug management before surgery, and provide 
technical advice for a variety of common clinical presentations. Further guidance on 
most aspects of interdisciplinary and interprofessional care for CD has been elaborated 





A detailed description of the methodology used is presented in the supplementary 
materials. This article is the second in a series of two publications relating to the ECCO 
evidence-based consensus on the management of CD. The first article [Torres J et al 
ECCO guidelines on therapeutics in CD, JCC 2020 in press] covered medical 
management; the present article addresses surgical management. Both articles 
together represent the evidence-based recommendations of the ECCO for CD and 
update prior guidelines published in 201617,18. These guidelines abide by the GRADE 
methodology in terms of framing clinically relevant questions to draw evidence-based 
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literature, appraisal of the systematically researched literature was conducted according 
to the Oxford methodology (Oxford Centre for Evidence-Based Medicine: the Oxford 
2011 Levels of Evidence 2 – grading from evidence level (EL) 1: systematic review of 
randomized controlled trials to EL 5: expert opinion19. This allowed us to formulate 
statements and practice recommendations that can be operationalized and can guide 
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Surgery for perineal disease 
 
Section 1. Complex perianal fistula 
 
Medical therapy and surgical drainage 
 
Statement 1.1 ECCO CD Treatment GL [2019]  
No prospective study directly compares medical or surgical treatment of complex 
perianal Crohn’s disease fistulae either in isolation or in combination with both 
modalities. Observational studies support a combined medical/surgical approach to 
control sepsis and luminal activity [EL5] 
 
No randomized controlled trials [RCT] or prospective studies were found that 
compared anti-TNF treatment alone versus anti-TNF and surgery combined to treat 
complex perianal CD fistulae. A heterogeneous group of retrospective studies that 
compared anti-TNF treatment with a variety of surgical approaches was combined in 
a meta-analysis published in 201420. The results of this analysis suggest that combined 
treatment “may have additional beneficial effects compared to surgical or medical 
treatment alone”. However, the heterogeneity of the included studies, the retrospective 
nature of the included analysis, and low study quality preclude any firm conclusions or 
recommendations. Recently, results of the PISA study were presented as an 
abstract21. PISA randomized patients with high perianal CD fistula and a single internal 
opening initially drained for 6 weeks to chronic seton drainage or anti-TNF for one year 
or advancement plasty under anti-TNF for 4 months. Primary outcome was fistula-
related re-intervention [surgery and/or re-initiation of anti-TNF]. This RCT was stopped 
after inclusion of 44 of 126 planned patients based on futility analysis. Chronic seton 
drainage was associated with the highest re-intervention rate within 1.5 year [10/15 vs. 
6/15 anti-TNF and 3/14 advancement plasty + anti-TNF patients, p =0.02]). No 
differences in quality of life and perianal disease activity index were observed. In a 
further prospective analysis of 50 patients, inferiority of chronic seton treatment could 
not be observed anymore for any outcome. The authors concluded that chronic seton 
treatment should not be recommended as the sole or superior treatment for perianal 
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In practice, management decisions remain with the physician and surgeon, considering 
clinical information and any resource implications. The key role of surgery is in 
controlling perianal sepsis by examination under anaesthesia and appropriate seton 
drainage. In this regard, successful medical therapy and minimizing the risk of anti-
TNF therapy depends upon a close liaison between the physician and surgeon. 
According to the summary of product characteristics registered and approved by the 
regulatory agencies, active sepsis or any infection is a clear contraindication to the use 
of infliximab or adalimumab. Therefore, any procedure likely to treat and prevent 
perianal sepsis is recommended as good clinical practice and must be performed 





Statement 1.2 ECCO CD Treatment GL [2019] 
Advancement flaps are a therapeutic option for patients with Crohn´s disease and 
complex perianal fistulae [EL4] 
 
A systematic review identified 11 retrospective studies that reported data from 135 
patients with CD perianal fistulae treated with an advancement flap22. The pooled 
success rate was 66%. However, definitions of success and length of follow-up were 
highly variable, the results were heterogeneous, and the overall evidence level was 
low. In a more recent meta-analysis, Stellingwerf et al. observed a 61% success rate 
in 35 patients with CD perianal fistula, which did not differ significantly from the success 
rate of a ligation of the intersphincteric fistula tract [LIFT] procedure [53%]. However, 
incontinence rates were significantly higher after flaps [7.8% versus 1.6%]23.  
As a RCT comparing advancement flap to no surgery would be unethical, collaborative 
efforts to collect larger numbers of cases undergoing advancement flap for perianal 
CD, with defined outcomes and follow-up, are required to better define the role of this 
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Statement 1.3 ECCO CD Treatment GL [2019] 
Fibrin glue may be a potential treatment with limited efficacy for patients with complex 
perianal Crohn’s disease [EL4]  
 
The use of fibrin glue for the treatment of CD perianal fistulae was assessed in an 
open-label RCT with 71 patients randomized to instillation of fibrin glue into the fistula 
tract or no further treatment after removal of seton24. Overall clinical remission rates at 
week 8 were 38% for fibrin glue and 16% in the observation group [p = 0.04]. There 
was no significant difference in adverse events, which were non-significantly higher in 
the observation group. Follow-up length in this RCT was insufficient for a definitive 
judgement on the true success rate. Several cohort studies with small numbers of CD 
patients reported a wide range of success rates with fibrin glue treatment. A uniform 
characteristic of all these studies is the relatively good safety profile of this technique, 
with no reported injury to the sphincter muscles, which may potentially justify 
attempting this technique in cognizant patients25. 
 
 
Statement 1.4 ECCO CD Treatment GL [2019] 
Ligation of the intersphincteric fistula tract is an option for treatment of patients with 
Crohn’s disease and complex perianal fistulae [EL4] 
 
LIFT is a recent option in the armamentarium of surgical treatments for perianal 
fistulae. Sirany et al. performed a systematic literature review and identified 26 studies 
that included a total of 713 patients, of which 13 had CD26. Among these studies was 
a single RCT (which however excluded CD patients) and 25 cohort or case series. 
Studies were heterogeneous with a wide range of outcome measures and follow-up 
times. The techniques used were only partially described and included seven technical 
variations. Primary healing rates ranged from 47–95%, thus even the lower end of this 
range appears promising when compared with other therapeutic options. Very few and 
minor complications were associated with classic LIFT and any of its variations [3 
complications were reported in 6 studies]. Göttgens et al. recently reported a 
retrospective cohort series of 46 patients mainly operated on for high transsphincteric 
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low [37%] and the median time to failure was 4.2 months. Moreover, 20% had new, 
mildly impaired faecal continence postoperatively. Conversely, a prospective study by 
Gingold et al. on 15 CD patients with complex perianal fistulae treated with LIFT 
revealed a 67% healing rate at 12 months and a significant improvement of faecal 
continence28. Overall, due to the paucity of data the role of LIFT for the treatment of 
perianal CD fistulae remains unclear, although the complication rate seems to be 
reasonably low. RCTs are needed to clarify the role of LIFT in CD fistulae, perhaps by 
comparing LIFT to advancement flap as a control arm. 
 
 
Statement 1.5 ECCO CD Treatment GL [2019] 
Anal Fistula Plugs (AFP) should not be routinely considered for ano-perineal fistulas 
closure in Crohn’s disease, as seton removal alone is equally effective [EL3] 
 
The use of collagen anal fistula plug [AFP] in patients with CD perianal fistulae was 
assessed in a single RCT, which compared seton removal with insertion of AFP into 
the fistula tract to seton removal and observation only in 106 CD patients29. After 12 
weeks, the fistula closure rate in the AFP group was 33.3% in patients with complex 
fistulae and 30.7% in patients with simple fistulae, as compared with 15.4% and 25.6% 
with seton removal alone, respectively. These differences were not statistically 
significant, perhaps because of an underpowered trial design. Importantly, there was 
a trend towards more adverse events at 12 weeks in the AFP group [17% vs. 8%; p = 
0.07]. However, cumulative adverse event rates at 12 months follow-up were similar. 
A systematic review of 12 observational studies included 84 patients with a median 
follow-up time of 9 [3–24] months30. The overall fistula closure rate was 58.3%, with 
40% success in the very small subgroup with a recurrent anal fistula from previous 
treatments. However, there was no uniform definition for fistula closure or follow-up 
regimen. The quality of evidence for this systematic review was rated low due to the 
risk of bias and imprecision.  
In the three largest studies that included both CD fistulae and non-CD fistulae31-33, the 
overall healing rate for CD fistulae was 47.0% versus 72.2% for non-CD fistulae. 
Repeating the plug procedure produced a lower success rate. Finally, a RCT that 
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advancement flap. Quality of life and anal pain improved in both groups, whereas the 
fistula closure rate at 1 year was significantly lower in the plug group than in the 
advancement flap group [34% vs. 62%; p = 0.006]. 
The use of AFP in patients with CD appears to be relatively safe and may be 
considered for selected patients aware of the low success rate. 
 
 
Statement 1.6 ECCO CD Treatment GL [2019] 
Ano- and rectogenital fistulae related to Crohn’s disease are very complex and rare; 
accordingly, they should be treated by an experienced multidisciplinary team [EL5] 
 
There is limited scientific evidence on the treatment of CD-associated rectovaginal 
fistulae. A systematic review by Kaimakliotis identified 23 studies [including 1 RCT, 6 
prospective studies, and 16 retrospective studies] with 137 CD-associated rectovaginal 
fistulae34. Of 23 reported studies, three studies included 43 rectovaginal fistulae that 
focused on combined medical and surgical treatment and revealed a healing rate of 
44.2%.  
Hotouras et al. reviewed 17 studies including 106 patients on the use of gracilis muscle 
interposition for rectovaginal fistulae35. Most studies were retrospective and non-
randomized and only 34 patients with CD fistulae were included. At a median follow-
up of 21 months, 50% of the CD fistulae undergoing gracilis muscle interposition had 
healed, as compared with 60–90% for non-CD rectovaginal fistulae. 
The repair of rectovaginal fistulae of CD is challenging and the selection of medical 
and/or surgical treatment should be considered on a case-by-case basis within an 
expert multidisciplinary team. 
 
 
Stem cell therapy 
 
Statement 1.7 ECCO CD Treatment GL [2019] 
Allogeneic adipose-derived stem cell therapy could be an effective and safe treatment 
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The use of allogeneic adipose-derived stem cells in patients with perianal fistulae of 
CD was assessed in a pivotal phase 3 RCT [ADMIRE CD trial] including 212 
patients36,37. All patients underwent curettage of the fistula tract and closure of the 
internal opening and were randomized to injection of stem cells or placebo around the 
internal opening and alongside the fistula tracts. Patients with more than two internal 
and three external openings, patients with rectovaginal fistula, and those with anal and 
rectal stenosis or proctitis were excluded from the study. At 1 year, there was 
significantly higher combined remission [defined as closure of the external opening on 
physical examination and absence of abscess in MRI] in the stem-cell treated patients 
compared with placebo [56.3% vs. 38.6%; p = 0.010].  
A meta-analysis of 11 studies, including 3 RCTs of which the ADMIRE CD was the 
largest38, showed improved healing rates when compared to the control arms.  
Allogeneic stem cell therapy seems to be safe. In the ADMIRE CD trial, serious 
adverse events did not significantly differ between the two groups, although the 
adverse event rate, mainly abscesses and fistulae, was slightly and not significantly 
higher in the treatment group compared with placebo [24.3% vs. to 20.6%]. There are 
currently no long-term follow-up data available on safety and effectiveness. 
The mode and technique of delivery of stem cells was not compared in any of the 
studies. Dozois et al. reported higher healing rates when stem cells were combined 
with fibrin glue or impregnated on a Gore Bio-A Fistula Plug versus direct injection 
[71% and 83% vs. 50%]39. While allogeneic stem cell therapy may be an effective and 
safe approach to treat complex perianal fistula, patient selection, optimal mode of 
delivery, and dose and frequency of injections should be determined in further studies.  
 
 
Statement 1.8 ECCO CD Treatment GL [2019] 
Autologous adipose-derived stem cells may have positive effect for patients with 
Crohn’s disease and complex perianal fistulae with good tolerability and safety [EL4] 
 
Autologous adipose-derived stem cells [ASC] have the advantage of originating from 
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autologous and allogenic stem cells require cost- and resource-intensive culture, 
expansion, and cryopreservation of the harvested ASC40. 
The best evidence on the use of ASC for perianal fistula of CD comes from an open-
label, phase 2 study including 43 patients41. Treatment included curettage, irrigation, 
and suturing of the internal opening. The fistula tract was filled with a mixture of ASCs 
and fibrin glue. ASCs were injected into the lesion site(s). A second injection of ASCs 
was performed for patients who did not show complete closure of the fistula at 8 weeks. 
After 12 months, 88.5% of the patients showed sustained fistula healing. A second trial 
was performed in 6 hospitals and included 24 patients, also allowing repeat ASC 
treatment when fistula closure was incomplete at week 12. At 6 months of follow-up, 
56.3% achieved complete clinical and MRI confirmed healing of the treated fistula42. A 
further phase 1 study included 12 patients and applied ASC in a bioabsorbable matrix 
[fistula plug] placed into the fistula, obtaining clinical and MRI confirmed healing at 6 
months in 10 of 12 patients [83%]43. In contrast to allogeneic stem cells, the use of 
autologous stem cells requires cell harvesting, which entails an additional procedure 
[liposuction]. Overall, the procedures appeared safe and the most common AEs were 
postoperative pain and anal bleeding. There are no studies comparing autologous and 
allogeneic stem cells for CD perianal fistula. 
Last, a recent prospective study investigated the effects of injecting freshly collected 
autologous adipose tissue into perianal CD fistulas. Twenty-one patients were treated 
with repeat injections offered when no healing was observed at 6 weeks, or later 
relapse occurred. Six months following the last adipose tissue injection, 12/21 patients 
(57%) had complete fistula healing confirmed by MRI and AE were minimal44. 
Harvesting, preparation, and administration of adipose tissue were performed as a 
single and inexpensive procedure. Further studies are required to define the true 
potential of this approach. 
 
 
Key points for clinical practice 
Complex perineal disease remains a challenging CD presentation. Innovative 
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therapeutic armamentarium. However, such novel approaches have yet to 
demonstrate effectiveness and consistent results in a properly designed RCT, with an 
adequate follow-up time [more than 1 year] and consistent imaging [MRI]. 
 
 
Section 2. Refractory pelvic sepsis 
 
Statement 2.1 ECCO CD Treatment GL [2019] 
Pelvic sepsis and symptoms from complex perineal Crohn’s disease refractory to 
medical or surgical interventions can be controlled by a diverting stoma. However, the 
fistula healing rate and stoma closure rate are limited [EL4] 
 
The quality of evidence for the use of defunctioning stoma in perianal CD is low, and 
no RCTs have compared defunctioning stoma to other surgical or medical 
interventions. There are several small and heterogeneous case series45-47 with variable 
stoma types and definitions of success. A meta-analysis of 16 cohort series including 
556 patients reported a clinical response in 63.8% of patients48. Clinical response was 
similar in the pre-biological era and in the biological era, respectively, and in patients 
failing biologics as in those not receiving biologics48,49. Restoration of bowel continuity 
was attempted in 34.5% of patients but was successful in only 16.6%. Absence of 
rectal involvement was consistently associated with restoration of continuity. Moreover, 
a quarter of the reversed patients required re-diversion [without proctectomy] because 
of severe recurrence. Ultimately, 41.6% of patients failed temporary diversion and 
required proctectomy. Similar results were reported in a later single-centre report of 77 
patients, of which 57 were concomitantly treated with biologics. Here, successful 
restoration of continuity was somewhat higher [27%] and reached 48% in the absence 
of ongoing perineal disease. 
Quality of life was not discussed in any of the studies. Despite the low evidence and 
the low rate of fistula healing, diverting stoma may offer an alternative to extensive 
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Key points for clinical practice 
The control of pelvic sepsis is multidisciplinary and draws from interventional radiology, 
infectious disease, gastroenterology, and surgery. Nutritional support is often key for 
optimal outcomes in this context, particularly if a stoma is created. Imaging [pelvic MRI 
or endosonography], swift seton drainage, antibiotics, intensified medical therapy, and 
specialist nursing care are the mainstay of treatment [Torres J et al ECCO guidelines 
on therapeutics in CD, JCC 2020 in press]. In cases of poor sepsis control, a diverting 




Surgical management of abdominal Crohn's disease 
 
Section 3. Approach to intra-abdominal abscess 
 
Statement 3.1 ECCO CD Treatment GL [2019] 
Percutaneous image-guided drainage of well-defined accessible intra-abdominal 
abscesses is recommended as the primary approach [EL4] 
 
The treatment of active CD complicated by intra-abdominal abscesses is challenging. 
Immunosuppression can be hazardous, antibiotic therapy may be insufficient for large 
abscesses. Furthermore, surgical drainage has an additional risk in the emergency 
setting/unfit patient, including the potential need for a stoma. Percutaneous drainage 
[PD] is advised as the primary treatment for well-defined unilocular abscesses when 
accessible by interventional radiology and has reported successful drainage rates of 
74–100%50. PD under ultrasonographic or computed tomographic guidance is a safe 
procedure with a low complication rate. When successful, PD may avoid subsequent 
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Statement 3.2 ECCO CD Treatment GL [2019] 
Following successful image-guided drainage of an intra-abdominal abscess, medical 
management without surgery may be considered. A low threshold for surgery is 
recommended in the event that medical management is not successful [EL4] 
 
There is a limited evidence on the optimal management of CD patients with intra-
abdominal abscess who underwent PD. In particular, the optimal timing of surgical 
intervention after abscess drainage is unknown. Up to 30% of patients may avoid 
surgery following successful PD52. Identifying those who may be treated without further 
surgery is challenging and presently relies on clinical judgment rather than on 
evidence. Nevertheless, elective surgery should be considered after sepsis 
control/resolution by PD and antibiotic therapy, as abscess recurrence is up to 6.5 
times greater following PD as stand-alone therapy than PD followed with surgical 
resection. Medically refractory disease, the presence of stenosis, or an 
enterocutaneous fistula, be it primary established or as a consequence of PD, increase 
the likelihood of surgery. Conversely, emergency surgery without prior PD and sepsis 
control is associated with a higher rate of complications and stoma than with initial PD 
followed by surgery53. Successful PD can be considered as a bridge to elective 
surgery, allowing nutritional and medical optimization and hence improved 
postoperative outcomes3,54.  
 
 
Key points for clinical practice 
The control of intra-abdominal abscesses resembles the approach to pelvic sepsis with 
interventional radiology, infectious disease, gastroenterology, and surgery involved, 
together with nutritional support. Frequent monitoring and surgical consultation are 
critical. Fortunately, surgery can be deferred in most cases. Definitive non-surgical 
management may be successful but must be carefully balanced and discussed with 
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Section 4. Preoperative optimization 
 
Statement 4.1 ECCO CD Treatment GL [2019] 
Preoperative nutritional assessment should be performed for all patients with Crohn's 
disease who need surgery. Nutritional optimization prior to surgery with enteral or 
parenteral nutrition is recommended for those patients with nutritional deficiencies 
[EL3]  
 
Nutritional deficiencies are common in CD patients who require surgery. Persistent or 
recurrent mucosal inflammation, enteric fistulae or strictures, chronic diarrhoea, and 
medication side effects impede nutritional status, which in turn is a major driver of 
medical and surgical outcomes55,56. Although RCTs are lacking, IBD referral centres 
have long integrated nutritional support into multidisciplinary teams. Several  
observational studies have shown that preoperative optimization in malnourished 
patients improves outcomes, including a meta-analysis of 1111 CD patients who 
received preoperative enteral or parenteral supplementation versus standard care57. 
Preoperative nutritional supplementation reduced postoperative complications [20% 
vs. 61.3%, odds ratio (OR) 0.26, 95% confidence interval (CI) 0.07–0.99; p < 0.001]. 
Enteral nutrition in particular led to markedly reduced postoperative morbidity [21.9% 
vs. 73.2%, OR 0.09, 95% CI 0.06–0.13, p<0.01] with a number needed to treat of 2. 
Goal-driven parenteral nutrition should be considered whenever enteral nutrition is 
hampered. Perioperative dietary therapy, including systematic nutritional screening, 
correction of deficits, and optimal preparation for surgery has been covered by 
Adamina et al. in a recent ECCO topical review addressing the needs of IBD patients 
before and after surgery3. 
 
 
ECCO Statement 4.2 
Preoperative corticosteroid use is associated with increased risk of postoperative 
complications [EL3]. Preoperative reduction of corticosteroid doses may reduce 
postoperative complications but should be monitored carefully to avoid increasing 
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Treatment with 20 mg prednisolone daily or equivalent for > 6 weeks is an 
acknowledged risk factor for surgical complications and hyperglycaemia, as reported 
in prior ECCO guidelines11,18. This has been extensively reported, although no large 
RCTs were dedicated to this issue. Two meta-analyses of prospective and 
retrospective cohort studies including 1714 IBD patients58 and 3807 CD patients59 
reported up to a doubling of surgical site infections for patients on steroids. Cut-offs for 
increased surgical complications were observed between 10 mg and 40 mg 
prednisolone daily for more than 3–6 weeks together with a uniform recommendation 
of tapering down steroids whenever possible prior to surgery. Conversely, thiopurines 
can be safely continued perioperatively7,11,18,58-62. A staged procedure with a temporary 
stoma may be considered when high-dose steroids cannot be weaned [emergency 
surgery] and/or when other risk factors are present [e.g. sepsis, malnutrition, smoking]. 
Lastly, little evidence supports the common practice of steroid stress dose 
administration perioperatively for patients on long-term corticosteroids over plain 
continuation of the preoperative dose, converted to intravenous equivalents where 
necessary63. Two small RCTs [37 patients] and five cohort studies [462 patients] did 
not demonstrate any benefit of steroid stress dose administration64. Testing of the 




Statement 4.3 ECCO CD Treatment GL [2019] 
Current evidence suggests that pre-operative treatment with anti-TNF therapy [EL3], 
vedolizumab [EL4], or ustekinumab [EL4] does not increase the risk of post-operative 
complications in patients with CD having abdominal surgery. Cessation of these 
medications prior to surgery is not mandatory 
 
Anti-TNF therapy 
The use of biologics in CD patients scheduled for surgery has been controversial. 
Concern was raised that by modulating the immune response, biologics may increase 
surgical site infections and morbidity. Some recent guidelines still caution against the 
use of anti-TNF therapy in this context, however the safest period of omission remains 
unknown11. The most recent meta-analysis on this subject included 18 non-
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not66. There were no differences in the occurrence of any complications between 
patients on infliximab or not: OR for major complications 1.41, 95% CI 0.85–2.34; OR 
for minor complications 1.14, 95% CI 0.81–1.61; OR for infectious complications 1.23, 
95% CI 0.87–1.74; OR for non-infectious complications 1.06, 95% CI 0.88–1.28; OR 
for readmission 1.46, 95% CI 0.8–2.66. This was also true for reoperation and mortality 
considered alone or included into major complications. Finally, results from the 
PUCCINI RCT presented as an abstract at the 2019 Digestive Disease Week that 
included 955 IBD patients showed that exposure to anti-TNF therapy, including the 
measurement of drug levels, had no effect on the occurrence of any surgical site 
infection or anastomotic leak. 
 
Vedolizumab 
Early data, including a retrospective multicentre analysis, comparing the postoperative 
outcomes of 146 patients receiving vedolizumab versus 289 patients on anti-TNF 
therapy revealed a significantly increased r te of surgical site infections after 
abdominal surgery in patients on vedolizumab67. However, the most recent meta-
analysis comparing 307 IBD patients treated with vedolizumab versus 490 patients on 
anti-TNF and 535 patients not exposed to preoperative biologic therapy revealed no 
differences in postoperative infectious and overall complications between vedolizumab 
patients and patients without biologic therapy [OR 0.99, resp. 1.00]. A similar outcome 
was observed when comparing patients on vedolizumab with those on anti-TNF 
therapy for the occurrence of postoperative infectious and overall complications [OR 
0.99, resp. 0.92]68. Although larger, randomized studies including perioperative drug 




Two retrospective multicentre cohort studies compared CD patients exposed 
preoperatively to either ustekinumab [for 3–6 months] or to anti-TNF therapy [follow-
up to 6 months postoperatively]. In univariate analysis, patients on ustekinumab were 
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therapy [25% vs. 2.5%; p = 0.01]69, and to be re-operated [16% vs. 5%; p = 0.01]70. 
Nevertheless, no increase in early and late postoperative complications were noted in 
multivariate analysis when comparing the surgical outcomes of those 60 patients on 
ustekinumab versus 209 patients receiving anti-TNF therapy69,70. Again, studies of 
better design and larger patient numbers are required to confirm these results. 
 
 
Statement 4.4 ECCO CD Treatment GL [2019] 
Preoperative control of sepsis is recommended prior to abdominal surgery for Crohn's 
disease [EL4] 
 
Surgery in the context of sepsis carries a high risk for postoperative complications, 
including anastomotic leaks and continued abdominal sepsis59. Preoperative control of 
sepsis with antibiotic therapy and PD of intra-abdominal abscess followed by elective 
surgery leads to lower rates of stoma creation, fewer complications, and shorter 
hospital length of stay when compared with emergency surgery and surgical 
drainage53,59,71. Prolonged [>6 weeks] and high-dose [≥20 mg prednisolone equivalent] 
steroids use are associated with poorer control of preoperative sepsis62. 
 
 
Key points for clinical practice 
Preoperative optimization is a key element in successful management of complex 
situations and chronic disease. Many aspects of optimal perioperative care are generic 
and common to all abdominal procedures72, although some aspects are  particularly 
important in the context of CD [venous thromboembolism prophylaxis, nutrition, iron 
management, drug management, minimally invasive approaches, and bowel- and 
sphincter-sparing techniques]54,73. A good relationship across disciplines and 
professions is critical. 
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Statement 5.1 ECCO CD Treatment GL [2019]  
Deferred surgery is the preferred option in adult patients with Crohn´s disease 
presenting with acute small-bowel obstruction without bowel ischaemia or peritonitis 
[EL4] 
 
Intestinal stenosis frequently occurs in the course of CD. Acute small-bowel obstruction 
typically presents with intractable nausea/vomiting, abdominal distension, and 
absence of gas or stool passage per anum. Conservative management is the preferred 
option in the absence of peritonitis, including bowel rest, gastric decompression, and 
intravenous fluid therapy. In the presence of active inflammatory disease, intravenous 
steroids should be considered11,17[+ Torres J et al ECCO guidelines on therapeutics in 
CD, JCC 2020 in press]. Primary conservative management allows optimization of the 
nutritional and immunosuppression status before a potential elective surgery3. 
Conversely, whenever clinical or radiological signs indicate an intestinal perforation, 
emergency surgery and resection of the diseased bowel loop are required. Early 
surgical consultation is strongly recommended to assess surgical indication and to 
jointly monitor the progress of a conservative approach. Episodes of (sub)acute small-
bowel obstruction also tend to recur over time, hence surgical advice is important in 
the context of interdisciplinary care and discussion of treatment options. 
 
Statement 5.2 ECCO CD Treatment GL [2019] 
Endoscopic balloon dilatation or surgery are both suitable treatment options for 
patients with short [<5 cm] strictures of the terminal ileum in Crohn’s disease. The 
choice of treatment depends on local expertise and patient preference [EL5] 
 
While symptomatic short strictures are frequent in CD patients, no RCT comparing 
surgery versus balloon dilatation has been performed. The largest study investigating 
the benefits and risks of balloon dilatation is a pooled analysis published in 2017 by 
Bettenworth et al. with 1493 patients who underwent a total of 3213 endoscopic balloon 
dilatations74. A total of 98.6% the strictures were ileal and 62% were anastomotic. The 
primary technical success rate [passage of the endoscope through the stricture] was 
89.1% and was 80.8% for clinical efficacy [symptom-free at completion of follow-up]. 
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Despite the high initial success rate, 73.5% of the patients underwent re-dilatation 
within 24 months and 42.9% required surgical resection.  
Similar results were reported in a systematic review by Morar et al. who analysed 1089 
patients and 2664 dilatations and reported a technical success rate of 90.6% and a 
clinical success rate of 70.2%. Complications occurred in 6.4% of the balloon 
dilatations. At 5 years of follow-up, 75% of the patients had undergone surgery75. There 
were no differences in outcomes when primary or anastomotic strictures were 
dilatated. Recent observational studies revealed comparable results76-79. Hence, 
balloon dilatation of both primary and anastomotic short CD strictures appears safe 
and effective in the short term. However, recurrence is the rule and the need for surgery 
is frequent in the following 5 years.  
 
 
Statement 5.3 ECCO CD Treatment GL [2019] 
Strictureplasty is a safe option to treat small bowel strictures related to Crohn's 
disease. Strictureplasty may be preferable to resection of long segments of bowel with 
potential reduction in surgical recurrence rates [EL3] 
 
Strictureplasty is an established and safe surgical option for treating strictures related 
to CD and is an alternative to bowel resection80,81. Strictureplasty is recommended 
whenever reasonable and technically feasible, particularly with multiple fibrotic 
strictures that would otherwise require more than a minimal bowel resection11,82. A 
meta-analysis of 1112 patients who underwent 3259 strictureplasties [81% Heineke-
Mikulicz, 10% Finney, 5% side-to-side isoperistaltic] prior to the biologic era revealed 
a 5-year recurrence rate of 28%83. Heineke-Mikulicz is the preferred technique for 
stenotic segments up to 6–8 cm, while Finney and side-to-side isoperistaltic techniques 
address longer or multiple strictures and require more expertise84. Surgical morbidity 
is in the range of 8–15% and is unrelated to stricture length84,85. Favourable long-term 
results have been reported81,84,85 and suggest better results for strictureplasty 
compared with resection. A large Japanese series reviewed 526 patients, of which 435 
underwent only bowel resections and 91 had a total of 199 strictureplasties. At 10 
years, the site-specific cumulative rate of reoperation was 18% at the anastomosis site 






















































































































Key points for clinical practice 
Whenever possible, elective surgery is preferable to an emergency procedure in acute 
small bowel obstruction due to a CD stenosis. This can be achieved in most scenarios 
with primary conservative management, such as rehydration and nasogastric 
decompression. An interdisciplinary discussion of the treatment options, which should 
also include the patient’s views, should follow. When surgery becomes necessary, it is 
important to thoroughly assess the bowel, ideally preoperatively with MRI 
enterography. MRI enterography may reveal a distinction between inflammatory 
strictures [amenable to intensified medical therapy] and fibrotic strictures. Assessing 
the bowel during surgery can also be very useful in identifying strictures. To maximize 
bowel preservation, the IBD surgeon should be familiar with the different kinds of 
strictureplasties, including non-conventional strictureplasties. Nonetheless, 
strictureplasty of the colon is not recommended11. 
 
 
Section 6. Surgical techniques for abdominal CD 
 
Statement 6.1 ECCO CD Treatment GL [2019] 
Laparoscopic surgery should be offered as the first line approach in surgery for Crohn's 
disease dependent on appropriate expertise [EL2] 
 
A meta-analysis and a Cochrane review of two RCTs87,88 showed no statistical 
difference in any outcomes between laparoscopic and open surgery for small-bowel 
CD. A more recent meta-analysis, which included RCTs and observational studies, 
revealed fewer complications and fewer incisional hernias in favour of the laparoscopic 
approach89. A further meta-analysis assessed laparoscopic resection for recurrent CD, 
confirming feasibility and safety in the presence of appropriate expertise90. Conversion 
to open surgery was 2.5 times more frequent in this context, although complications 
did not increase. Hence, patients benefit from a laparoscopic approach in surgery for 
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fewer incisional hernias. In the absence of expertise to perform laparoscopic surgery, 
emergency operations should not be delayed. 
 
 
Statement 6.2 ECCO CD Treatment GL [2019] 
A temporary stoma should be considered if steroids cannot be withdrawn or 
significantly reduced prior to surgery [EL5] 
 
The decision to create a stoma [primary anastomosis and protective stoma or no 
anastomosis and split stoma] in the context of steroid intake relies mostly on clinical 
grounds and experience. There are no data comparing strategies with primary 
anastomosis or secondary anastomosis in CD patients treated with steroids. However, 
prolonged [>6 weeks] and high-dose [≥20 mg prednisolone equivalent] steroid use are 




Statement 6.3 ECCO CD Treatment GL [2019] 
Primary anastomosis may safely be performed in the presence of anti-TNF therapy 
[EL3], vedolizumab [EL4], and ustekinumab [EL4], provided other risk factors have 
been accounted for 
 
As discussed earlier in these guidelines, the effect of anti-TNF therapy on anastomosis 
healing has been largely studied, although large RCTs that definitively address this 
important issue are lacking. Overall, the administration of anti-TNF therapy does not 
seem to increase anastomotic risk. However, anti-TNF therapy cannot be isolated from 
its clinical context, neither when facing an individual patient nor in appraising the 
literature in which several biases confound the evaluation of the true effect of anti-TNF 
therapy [e.g. heterogeneity of inclusion criteria and clinical presentation/risk factors, 
duration and dose of anti-TNF therapy administered, combination therapy, absence of 
drug monitoring]. The same considerations apply to vedolizumab and ustekinumab, in 
which the challenges of data evaluation are further compounded by less clinical 






















































































































Statement 6.4 ECCO CD Treatment GL [2019] 
Laparoscopic resection in patients with limited, non-stricturing, ileocaecal Crohn’s 
disease ([diseased terminal ileum < 40 cm] is a reasonable alternative to infliximab 
therapy [EL2] 
 
Prior ECCO guidelines have declared [laparoscopic] resection as the preferred option 
in patients with localized ileocaecal CD with obstructive symptoms but no active 
inflammation11.  
For active non-stenotic disease, a recent randomized multicentre European trial 
compared 143 patients with active, non-stricturing disease involving < 40 cm of the 
terminal ileum in whom conventional therapy had failed to either infliximab or 
laparoscopic ileocaecal resection119. There was no difference in the primary outcome 
of quality of life on the Inflammatory Bowel Disease Questionnaire at 12 months or in 
general quality of life as measured by the Short Form-36 health survey. However, 
operated patients scored 3.1 points better [95% CI 4.2–6.0] in the physical subscale of 
this survey. Serious complications were not different between medical and surgical 
groups. Over a median follow-up of 4 years, 37% of the infliximab-treated patients 
required resection, whereas 26% of the primary resected patients were put on 
infliximab. Hence, laparoscopic resection of both stricturing, fibrotic disease of the 
terminal ileum and of an actively diseased terminal ileum [< 40 cm] can be offered as 
a sound therapeutic option in an interdisciplinary context with a benefit and risk profile 
comparable to medical therapy. 
 
 
Statement 6.5 ECCO CD Treatment GL [2019] 
Stapled small-bowel or ileocolic side-to-side anastomoses are associated with lower 
rates of postoperative complications than end-to-end anastomoses in Crohn’s disease 
[EL3] 
 
Technical aspects are important to surgeons and can be influenced by many factors, 
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The optimal choice of anastomosis technique in small-bowel and ileocolic resection 
has been controversial. In the last 10 years, evidence in favour of a side-to-side 
anastomosis has emerged and was confirmed over time. The first large meta-analysis 
by Simillis et al. included 661 patients and revealed that the anastomotic leak rate was 
higher for an end-to-end anastomosis versus side-to-side anastomosis [OR 4.37; p = 
0.02], including the subgroup of ileocolic anastomosis [OR 3.8; p = 0.05]120. Overall 
postoperative complications [OR 2.64; p < 0.001] and length of hospital stay were 
accordingly higher [by 2.81 days, p = 0.007] when an end-to-end anastomosis was 
performed. A later meta-analysis by Guo et al. confirmed the superiority of a side-to-
side anastomosis over other configurations in terms of overall postoperative 
complications [OR 0.6, p = 0.01]. However, there were no statistically significant 
differences for leak rate, endoscopic and symptomatic recurrence, and reoperation for 
recurrence121. A further meta-analysis by He et al. compared 396 stapled side-to-side 
with 425 hand-sewn end-to-end anastomoses. Stapled side-to-side anastomoses were 
superior in all endpoints: overall postoperative complications [OR 0.54, 95% CI 0.32–
0.93], anastomotic leak [OR 0.45, 95% CI 0.20–1.00], recurrence [OR 0.20, 95% CI 
0.07–0.55], and re-operation for recurrence [OR 0.18, 95% CI 0.07–0.45]122. Finally, a 
network meta-analysis of 11 trials and 1113 patients confirmed the superiority of 
stapled side-to-side anastomosis in terms of overall complications, clinical recurrence, 
and reoperation for recurrence. Leak rate, surgical site infections, mortality, and length 
of stay were not affected by the choice of the anastomosis technique123. The quality of 
the studies included in all meta-analyses was low with a minority of patients included 
in RCTs. The general conclusion favours stapled side-to-side anastomosis. The 
diameter of the anastomosis likely plays a role, with an assumption that a wider 
anastomosis will have a lower rate of clinical and surgical recurrences. 
 
 
Statement 6.6 ECCO CD Treatment GL [2019] 
Segmental colectomy is appropriate for patients with a single involved colonic segment  
in Crohn’s disease [EL3] 
 
When a single colonic segment is involved, a segmental colectomy is indicated. 
Multiple involved colon segments generally indicate a (sub)total colectomy as the 
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colectomies with ileorectal anastomosis to 265 segmental colectomies for colonic 
CD124. While the recurrence rates, complications, and need for a permanent stoma 
were not different, recurrence occurred 4.4 years later in the subtotal/total colectomy 
[p < 0.001]. A recent meta-analysis by Angriman et al. evaluated 1436 patients who 
received segmental colectomy [n = 500], subtotal colectomy [n = 510], or total 
proctocolectomy [n = 426]125. Complications were more frequent after segmental 
colectomy than subtotal colectomy [OR 2.84, 95% CI 1.16–6.96] and after 
proctocolectomy than subtotal colectomy [OR 0.19, 95% CI 0.09–0.38]. Hence, 
subtotal colectomy appeared to be the safer procedure, although segmental colectomy 
resulted in fewer permanent stoma than subtotal colectomy [OR 0.52, 95% CI 0.35–
0.77]. Regarding CD recurrence, subtotal colectomy showed higher CD recurrence 
[OR 3.53, 95% CI 2.45–5.10] and need for repeat surgery [OR 3.52, 95% CI 2.27–
5.44] than total proctocolectomy, whereas no difference in recurrence was observed 
between segmental colectomy and subtotal colectomy. In the rare situation where two 
distinct colon segments are involved, two segmental resections can be considered 
instead of a subtotal colectomy11, particularly for the patient who has suffered an 
extensive loss of small bowel. In summary, the extent of colonic resection is indicated 
by the clinical situation [elective vs. emergency surgery] and the number of colonic 
segments involved. Segmental colectomy is preferred whenever possible.  
 
 
Statement 6.7 ECCO CD Treatment GL [2019] 
A defunctioning stoma for non-acute refractory Crohn’s colitis may delay or avoid the 
need for colectomy [EL5] 
 
The following two options may be discussed in the presence of refractory CD colitis: a 
(sub)total colectomy, particularly as a potentially life-saving procedure in fulminant 
colitis, and a defunctioning ileostomy to divert the faecal stream and allow for 
remission, together with intensified medical therapy126. A diverting ileostomy may delay 
further procedures, facilitate perioperative optimization, and allow for a limited 
resection if required at a later stage [i.e. segmental colectomy]. The clinical scenario 
in which a diverting stoma is performed to aid the management of extensive perineal 
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The literature prior to the biologic era reports initial remission rates of approximately 
90%45,127-129 following creation of a defunctioning stoma, which is less than the 50– 
80% reported in more recent series130,131. Lasting restoration of bowel continuity/stoma 
reversal was effective in up to two-thirds of the patients but was much less when 
perineal disease was also present [i.e. 29–42%]130,131. Surgical complications of 
defunctioning stoma creation were in the expected range of 3–10% for stoma 
prolapse/hernia and < 5% renal failure due to high-output stoma130. Further bowel 
resection was reported in up to half of the patients in recent series130,131. Risk factors 
for (procto)colectomy were severe refractory perineal disease, requirement for 
combined medical therapy, and a history of >1 biologic drug. For these patients, early 




Statement 6.8 ECCO CD Treatment GL [2019] 
Restorative proctocolectomy with ileal pouch-anal anastomosis can be considered in 
selected patients with refractory pancolonic Crohn’s disease without history of perianal 
disease, taking into account the high risk of pouch failure [EL4] 
 
Several expert centres have reported their experience with restorative proctocolectomy 
and ileal pouch-anal anastomosis [IPAA] for refractory pancolonic CD. Prior ECCO 
guidelines stressed the higher complication and failure rates of CD-IPAA, which should 
be restricted to highly motivated patients and to multidisciplinary teams, and only in the 
absence of small-bowel and perineal diseases11. 
Panis et al. compared 31 CD-IPAA patients without small-bowel or perianal 
involvement with 71 ulcerative colitis IPAA [UC-IPAA] patients. No difference in 
postoperative outcomes were reported, whereas the 5-year definitive end ileostomy 
rate was 10% in CD-IPAA versus 2% in UC-IPAA patients132. At 10 years of follow-up, 
rates of CD-related complications were 35% with 10% of the pouches excised133. 
Manilich et al.134 and Fazio et al.135 reported two large comparative series from the 
same institution for a total of 3754 consecutive patients, of which 150 were CD-IPAA 
patients. Again, no differences in early complications [pelvic sepsis, anastomotic leaks] 
were observed. However, CD-IPAA patients had a higher pouch failure rate [13.3%] 


















































































































Manuscript Doi: 10.1093/ecco-jcc/jjz187 
28 
respectively]. At 10 years, 80% of CD-IPAA patients retained a functional pouch versus 
95% in UC-IPAA and indeterminate colitis IPAA. 
Reese et al.136 performed a meta-analysis of 3103 patients, of whom 225 were CD-
IPAA and suffered from twice as many anastomotic strictures and six times more pouch 
failures [32% vs 4.8%, p < 0.01]. However, in patients with isolated colonic CD, no 
significant difference in postoperative complications or pouch failure [8% in CD-IPAA 
patients vs. 7.1% in UC-IPAA patients] was observed. Importantly, patients with 
isolated colonic CD did not have more complications or pouch failures than UC 
patients. Nevertheless, IPAA function was poorer in CD patients [two times more 
incontinence and urgency], although stool frequency did not differ. Similarly, no 
difference in quality-of-life scores were reported in the large Cleveland series, 




There are many options and crossroads in decision making for surgery in CD. Some 
approaches have been tested over time and were described in these surgical 
guidelines. 
Although sufficient training, technical expertise, and an adequate caseload to achieve 
and maintain subspecialization in IBD surgery are important, the key to success in 
managing CD is a multidisciplinary team, as no specialist alone can solve the CD 
equation.  
The present guidelines have been written with this interdisciplinary spirit in mind and 
summarize the current knowledge at hand. The degree of certainty in some aspects of 
surgery for CD is closer to eminence than evidence, thus paving the way for further 
research and better answers. Revealing gaps in evidence is the first step to resolution, 
as research focused on clinical needs and gaps in the current evidence will inform 
guideline updates. Meanwhile, dynamic integration of gains in knowledge into the 
ECCO e-Guide will allow for rapid dissemination. Guidelines provide guidance to the 
clinician, who adapt expert knowledge and generic evidence to individualize care. It is 
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